130 related articles for article (PubMed ID: 11595290)
21. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
[TBL] [Abstract][Full Text] [Related]
22. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
[TBL] [Abstract][Full Text] [Related]
23. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK
J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809
[TBL] [Abstract][Full Text] [Related]
24. Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes.
Sun Y; Schmitz JE; Acierno PM; Santra S; Subbramanian RA; Barouch DH; Gorgone DA; Lifton MA; Beaudry KR; Manson K; Philippon V; Xu L; Maecker HT; Mascola JR; Panicali D; Nabel GJ; Letvin NL
J Immunol; 2005 Apr; 174(8):4753-60. PubMed ID: 15814700
[TBL] [Abstract][Full Text] [Related]
25. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques.
Cherpelis S; Jin X; Gettie A; Ho DD; Barnett SW; Shrivastava I; Stamatatos L
Immunol Lett; 2001 Nov; 79(1-2):47-55. PubMed ID: 11595289
[TBL] [Abstract][Full Text] [Related]
26. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
Schmitz JE; Kuroda MJ; Santra S; Sasseville VG; Simon MA; Lifton MA; Racz P; Tenner-Racz K; Dalesandro M; Scallon BJ; Ghrayeb J; Forman MA; Montefiori DC; Rieber EP; Letvin NL; Reimann KA
Science; 1999 Feb; 283(5403):857-60. PubMed ID: 9933172
[TBL] [Abstract][Full Text] [Related]
27. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
[TBL] [Abstract][Full Text] [Related]
28. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
[TBL] [Abstract][Full Text] [Related]
30. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.
Silvera P; Richardson MW; Greenhouse J; Yalley-Ogunro J; Shaw N; Mirchandani J; Khalili K; Zagury JF; Lewis MG; Rappaport J
J Virol; 2002 Apr; 76(8):3800-9. PubMed ID: 11907220
[TBL] [Abstract][Full Text] [Related]
31. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.
Patterson LJ; Malkevitch N; Venzon D; Pinczewski J; Gómez-Román VR; Wang L; Kalyanaraman VS; Markham PD; Robey FA; Robert-Guroff M
J Virol; 2004 Mar; 78(5):2212-21. PubMed ID: 14963117
[TBL] [Abstract][Full Text] [Related]
32. Loss of reactivity of vaccine-induced CD4 T cells in immunized monkeys after SIV/HIV challenge.
Puaux AL; Delache B; Marconi S; Huerre M; Le Grand R; Rivière Y; Michel ML
AIDS; 2005 May; 19(8):757-65. PubMed ID: 15867489
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic dendritic-cell vaccine for simian AIDS.
Lu W; Wu X; Lu Y; Guo W; Andrieu JM
Nat Med; 2003 Jan; 9(1):27-32. PubMed ID: 12496959
[TBL] [Abstract][Full Text] [Related]
34. The critical role of CD4(+) T-cell help in immunity to HIV.
Heeney JL
Vaccine; 2002 May; 20(15):1961-3. PubMed ID: 11983254
[TBL] [Abstract][Full Text] [Related]
35. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.
Chong SY; Egan MA; Kutzler MA; Megati S; Masood A; Roopchard V; Garcia-Hand D; Montefiori DC; Quiroz J; Rosati M; Schadeck EB; Boyer JD; Pavlakis GN; Weiner DB; Sidhu M; Eldridge JH; Israel ZR
Vaccine; 2007 Jun; 25(26):4967-82. PubMed ID: 17335943
[TBL] [Abstract][Full Text] [Related]
36. Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2.
Sadagopal S; Amara RR; Montefiori DC; Wyatt LS; Staprans SI; Kozyr NL; McClure HM; Moss B; Robinson HL
J Virol; 2005 Mar; 79(6):3243-53. PubMed ID: 15731219
[TBL] [Abstract][Full Text] [Related]
37. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys.
Santra S; Schmitz JE; Kuroda MJ; Lifton MA; Nickerson CE; Lord CI; Pal R; Franchini G; Letvin NL
J Immunol; 2002 Feb; 168(4):1847-53. PubMed ID: 11823518
[TBL] [Abstract][Full Text] [Related]
38. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.
Heeney J; Akerblom L; Barnett S; Bogers W; Davis D; Fuller D; Koopman G; Lehner T; Mooij P; Morein B; de Giuli Morghen C; Rosenwirth B; Verschoor E; Wagner R; Wolf H
Immunol Lett; 1999 Mar; 66(1-3):189-95. PubMed ID: 10203054
[TBL] [Abstract][Full Text] [Related]
40. Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.
Santra S; Barouch DH; Kuroda MJ; Schmitz JE; Krivulka GR; Beaudry K; Lord CI; Lifton MA; Wyatt LS; Moss B; Hirsch VM; Letvin NL
J Virol; 2002 Jun; 76(12):6376-81. PubMed ID: 12021371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
